Valuation dashboard for Eledon Pharmaceuticals, Inc. (ELDN) with P/E N/A, P/B 4.21, EV/EBITDA -2.80 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $2.67, ELDN has negative trailing earnings (P/E not meaningful) and an ROE of -136.45%. Market capitalisation stands at $206M.
Balance sheet quality for ELDN: current ratio of 7.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 4.21 |
| EV / EBITDA | -2.80 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.24 |
| vs Current Price | -91.2% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ELDN | Eledon Pharmaceuticals, Inc. | $206M | 4.21 | -136.4% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.67 |
| Market Cap | $206M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -136.45% |
| Return on Invested Capital | -73.77% |
| Return on Assets | -78.16% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABEO · ACHV · ALLO · AVIR · EDIT · HUMA · PBYI
Explore sector: Healthcare · Biotechnology
More sections of ELDN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks